Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCRS EPICAT
DRKS00026178Phase 3Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of bromfenac sodium, dexamethasone, triamcinolone acetonide and phenylephrine + ketorolac in cataract and cystoid macular edema (CME) (4 arms), sponsored by Maastricht University Medical Center+. Started May 2022; status: recruiting.
02
Drugs
bromfenac sodiumdexamethasonetriamcinolone acetonidephenylephrine + ketorolac
03
Conditions
cataractcystoid macular edema (CME)
Beyond the preview
Go deeper on DRKS00026178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00026178.